Omega Diagnostics has signed an agreement to make up to 46,000 Covid-19 antibody tests a day on behalf of London-based biotech firm Mologic.
The Clackmannanshire-based business today announced a material transfer agreement to allow Mologic access to its facility in Littleport, Cambridgeshire, to to manufacture its Elisa test.
The test has been part-funded by the UK Government and is designed to indicate whether people have had the Covid-19 virus, may have immunity to it and could therefore return to relatively normal life.
Omega staff have been given access to the materials and knowhow to produce the test and the companies have collaborated to produce pilot batches and first validation batches.
Omega chief executive Colin King said: "We are pleased that Omega has been able to support Mologic with the development and scale up of their ELISA test. This is another example of the UK diagnostics industry working in collaboration to bring effective solutions in the fight against this global pandemic."
The Elisa test has ben independently validated by the Liverpool School of Tropical Medicine and St George's, University of London, and the test has been given to Public Health England and NHS Scotland for formal validation.
Omega is also part of a consortium working on a lateral flow antibody test which could quickly show presence of Covid-19 antibodies, which will be made at Omega's base in Alva.
